CANbridge Pharmaceuticals Inc.
HKEX:1228.HK
0.195 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 102.871 | 78.972 | 31.161 | 12.032 | 1.469 |
| Cost of Revenue
| 38.707 | 30.078 | 12.385 | 5.154 | 0.504 |
| Gross Profit
| 64.164 | 48.894 | 18.776 | 6.878 | 0.965 |
| Gross Profit Ratio
| 0.624 | 0.619 | 0.603 | 0.572 | 0.657 |
| Reseach & Development Expenses
| 257.21 | 311.174 | 427.658 | 109.642 | 55.383 |
| General & Administrative Expenses
| 89.83 | 108.907 | 145.517 | 43.659 | 22.152 |
| Selling & Marketing Expenses
| 83.671 | 86.782 | 100.748 | 51.008 | 28.881 |
| SG&A
| 173.501 | 195.689 | 246.265 | 94.667 | 51.033 |
| Other Expenses
| 0 | -31.425 | -466.606 | -591.295 | -78.945 |
| Operating Expenses
| 64.164 | 498.409 | 673.518 | 237.971 | 137.81 |
| Operating Income
| -366.547 | -477.047 | -1,118.108 | -821.503 | -216.309 |
| Operating Income Ratio
| -3.563 | -6.041 | -35.882 | -68.277 | -147.249 |
| Total Other Income Expenses Net
| -12.29 | -6.428 | 41.102 | -614.95 | -80.83 |
| Income Before Tax
| -378.837 | -483.475 | -1,077.006 | -846.043 | -217.675 |
| Income Before Tax Ratio
| -3.683 | -6.122 | -34.563 | -70.316 | -148.179 |
| Income Tax Expense
| 0 | 21.75 | 15.469 | 17.633 | 3.423 |
| Net Income
| -378.837 | -483.475 | -1,077.006 | -846.043 | -217.675 |
| Net Income Ratio
| -3.683 | -6.122 | -34.563 | -70.316 | -148.179 |
| EPS
| -0.89 | -1.14 | -11.43 | -1.99 | -0.51 |
| EPS Diluted
| -0.89 | -1.14 | -11.43 | -1.99 | -0.51 |
| EBITDA
| -341.429 | -454.634 | -1,058.221 | -824.41 | -212.731 |
| EBITDA Ratio
| -3.319 | -5.762 | -35.378 | -66.794 | -144.802 |